RecruitingNot ApplicableNCT04029363
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
Sponsor
HighLife SAS
Enrollment
120 participants
Start Date
May 28, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
to evaluate the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a medical device called HighLife Transcatheter Mitral Valve Replacement for people with mitral regurgitation. The study is currently recruiting participants at 50 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEHighLife Transcatheter Mitral Valve Replacement
Transcatheter Mitral Valve Replacement
Locations(50)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04029363
Related Trials
ATLAS (AltaValve) Pivotal Trial
NCT0646574529 locations
The REValve Clinical Trial an Evaluation Of the ReValve Palmetto Valve for the Replacement of the Native Mitral VaLVE
NCT074509113 locations
Capstan Medical TMVR Study: FIH
NCT066001913 locations
Cephea Early Feasibility Study
NCT0506100422 locations
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
NCT0549699837 locations